Session Details
[GS01]Young pharmaceutical scientists accelerate translational research in infectious disease
Sat. Mar 27, 2021 9:30 AM - 11:30 AM JST
Sat. Mar 27, 2021 12:30 AM - 2:30 AM UTC
Sat. Mar 27, 2021 12:30 AM - 2:30 AM UTC
[Room E] Oral Presentation E Online
Organizer: Sho Tashiro (Keio Univ., Fac. Pharm., Grad. Sch. Pharm. Sci.), Chika Ogami (Pharm. Univ. Toyama)
Antimicrobial-resistant bacteria are the cause of death in an estimated 700,000 people annually worldwide, and this number is predicted to increase to 10 million by 2050 if efforts are not made to reduce resistance or develop new antibiotics. Therefore, research, development, and proper use of antibiotics are urgent issues. However, development is decreasing, and misuse and abuse remain common, which lead to their spread.
In this symposium, 6 young pharmaceutical scientists will present from varying backgrounds of infectious research (pre-clinical studies [PCS] ~ clinical studies [CS]). Young scientists who are actively trying to overcome the threat and improve clinical antibacterial chemotherapy will share novel medical seeds found in daily research and their opinions. These seeds are expected to advance both PCS and CS, which will aid in the development of new therapies.
After this symposium, young scientists who are performing PCS and CS are anticipated to collaborate organically with each other to develop innovative next-generation treatments. We consider this symposium to be a shortcut to overcoming antimicrobial-resistant bacteria.
In this symposium, 6 young pharmaceutical scientists will present from varying backgrounds of infectious research (pre-clinical studies [PCS] ~ clinical studies [CS]). Young scientists who are actively trying to overcome the threat and improve clinical antibacterial chemotherapy will share novel medical seeds found in daily research and their opinions. These seeds are expected to advance both PCS and CS, which will aid in the development of new therapies.
After this symposium, young scientists who are performing PCS and CS are anticipated to collaborate organically with each other to develop innovative next-generation treatments. We consider this symposium to be a shortcut to overcoming antimicrobial-resistant bacteria.
オーガナイザー挨拶：田代 渉（慶應大薬）
[GS01-1]Antimicrobial resistance of Pseudomonas. aeruginosa.: Differences of resistant mechanisms between clinical isolates and laboratory isolates.
○Itsuki Wakisaka1, Masaya Endou1, Daichi Morita1,2, Shizuo Kayama3,4,5, Atsushi Ota6, Takanori Kumagai1,2, Humito Maruyama6, Motoyuki Sugai3,4,5, Teruo Kuroda1,2 (1. Sch. Phar., Hiroshima Univ, 2. Dept. Microbiol., Grad. Sch. Biomed. Heal. Sci., Hiroshima Univ., 3. Anti. Resis. Res. Cent., Nat. Inst. Infect. Dis., 4. Proj. Res. Cent. Noso. Infect. Dis., Hiroshima Univ., 5. Dept. Anti. Res., Grad. Sch. Biomed. Heal. Sci., Hiroshima Univ., 6. Dept. Microb. Gen. Ecol. Lab., Office Acad. Res. Indust. Gov. Commun. Collaboration, Hiroshima Univ.)
[GS01-2]Efficacy of in vitro rifampicin combination therapy against biofilm-producing S. aureus
○Takashi Uno1,2, Takumi Sato1, Ryota Ito1, Masato Kawamura1, Shigeru Fujimura1 (1. Tohoku Med. Pharm. Univ., 2. Tohoku Med. Pharm. Univ. Hosp.)
[GS01-3]PK/PD evaluation of existing antimicrobials against ESBL-producing E. coli in in vitro and in vivo a murine thigh infection model
○Sho Tashiro1, Kazuaki Matsumoto1 (1. Keio Univ., Fac. Pharm., Grad. Sch. Pharm. Sci.)
[GS01-4]Pharmacometrics modelling to predict pharmacokinetics and clinical efficacy of teicoplanin
○Chika Ogami1, Yasuhiro Tsuji2, Yuichi Muraki3, Masahiro Okuda4, Hideto To1 (1. Pharm. Univ. Toyama, 2. Pharm. Nihon Univ., 3. Pharm. Kyoto-yakka Univ., 4. Pharm. Hosp. Osaka)
[GS01-5]Individualized dosing regimens of ampicillin-sulbactam based on physiologically-based pharmacokinetics/pharmacodynamics model analysis
○Tetsushu Onita1,2 (1. Dept. Clin. Pharmacother, Hiroshima Univ., 2. Dept. Pharm, Shimane Univ. Hosp.)
[GS01-6]Construction of a simple flowchart to predict the risk of vancomycin induced acute kidney injury ~utilizing data mining methods in infectious disease therapy~
○Takayuki Miyai1, Shungo Imai2, Mitsuru Sugawara2,3 (1. Grad. Sch. Life Sci., Hokkaido Univ., 2. Grad. Sch. Pharm. Sci., Hokkaido Univ., 3. Dept. Pharm., Hokkaido Univ. Hosp.)